Online inquiry

IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9587MR)

This product GTTS-WQ9587MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VSIR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_022153.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64115
UniProt ID Q9H7M9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9587MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8099MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ7014MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ15309MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ4693MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ14059MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ9346MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ4688MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ9445MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH4102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW